These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31842910)

  • 1. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
    Sheng L; Cui X; Cheng L; Chen Y; Du X
    Radiat Oncol; 2019 Dec; 14(1):229. PubMed ID: 31842910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
    Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
    Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
    Dang J; Li G; Zang S; Zhang S; Yao L
    Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
    Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
    Guilbault C; Garant A; Faria S; Owen S; Ofiara L; Duclos M; Hirsh V; Kopek N
    Clin Lung Cancer; 2017 Sep; 18(5):565-571. PubMed ID: 28344046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
    Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
    Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
    Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
    Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
    Jia W; Gao Q; Wang M; Li J; Jing W; Yu J; Zhu H
    Radiat Oncol; 2021 Feb; 16(1):41. PubMed ID: 33622352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study.
    Farr KP; Kallehauge JF; Møller DS; Khalil AA; Kramer S; Bluhme H; Morsing A; Grau C
    Radiother Oncol; 2015 Oct; 117(1):9-16. PubMed ID: 26303012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
    Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
    Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy.
    Kirakli EK; Erdem S; Susam S; Erim E
    J Cancer Res Ther; 2023; 19(5):1153-1159. PubMed ID: 37787278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
    Piotrowski T; Matecka-Nowak M; Milecki P
    Neoplasma; 2005; 52(1):56-62. PubMed ID: 15739028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
    Kim TH; Cho KH; Pyo HR; Lee JS; Zo JI; Lee DH; Lee JM; Kim HY; Hwangbo B; Park SY; Kim JY; Shin KH; Kim DY
    Radiology; 2005 Apr; 235(1):208-15. PubMed ID: 15703313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer.
    Ogata T; Katsui K; Yoshio K; Ihara H; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Acta Med Okayama; 2018 Oct; 72(5):507-513. PubMed ID: 30369608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the radiation pneumonia development risk in lung cancer cases.
    Yilmaz S; Adas YG; Hicsonmez A; Andrieu MN; Akyurek S; Gokce SC
    Asian Pac J Cancer Prev; 2014; 15(17):7371-5. PubMed ID: 25227844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.